Table 2 Clinical markers of the study participants at baseline (M0), JUSH, Southwest Ethiopia, 2007.
Characteristics | Fr (%) |
|---|---|
WHO disease stage when HAART started (N = 400) | Â |
   I | 3(.8) |
   II | 33(8.3) |
   III | 265(66.3) |
   IV | 99(24.8) |
CD4 count when the treatment was started (N = 374) | Â |
   ≥ 500 | 3(.8) |
   200–499 | 101(27.0) |
   < 200 | 270(72.2) |
Duration of treatment in months (N = 400) | Â |
   3–12 | 279(69.8) |
   13–24 | 112(28.0) |
   ≥ 25 | 9(2.3) |
Clinical Follow Up (N = 400) | Â |
   Monthly | 384(96.0) |
   Every two month | 15(3.8) |
   Every three month | 1(.3) |